Peak Bio (NASDAQ:PKBO) and ADMA Biologics (NASDAQ:ADMA) Financial Analysis

Peak Bio (NASDAQ:PKBO) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Profitability

This table compares Peak Bio and ADMA Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Peak Bio	N/A	N/A	-253.92%
ADMA Biologics	10.53%	38.79%	17.35%

Valuation & Earnings

This table compares Peak Bio and ADMA Biologics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Peak Bio	$370,000.00	11.25	-$12.83 million	N/A	N/A
ADMA Biologics	$330.24 million	13.61	-$28.24 million	($0.02)	-969.25

Peak Bio has higher earnings, but lower revenue than ADMA Biologics.

Volatility & Risk

Peak Bio has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Peak Bio and ADMA Biologics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Peak Bio	0	0	0	0	N/A
ADMA Biologics	0	0	3	1	3.25

ADMA Biologics has a consensus target price of $15.50, suggesting a potential downside of 20.04%. Given ADMA Biologics’ higher possible upside, analysts plainly believe ADMA Biologics is more favorable than Peak Bio.

Insider & Institutional Ownership

75.7% of ADMA Biologics shares are held by institutional investors. 19.9% of Peak Bio shares are held by company insiders. Comparatively, 3.7% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

ADMA Biologics beats Peak Bio on 10 of the 12 factors compared between the two stocks.

About Peak Bio

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.